Phathom Pharmaceuticals (PHAT) Competitors $8.78 -0.31 (-3.41%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends PHAT vs. ORIC, INVA, ARQT, NKTX, OCUL, MRUS, IBRX, PTCT, AGIO, and BHCShould you be buying Phathom Pharmaceuticals stock or one of its competitors? The main competitors of Phathom Pharmaceuticals include ORIC Pharmaceuticals (ORIC), Innoviva (INVA), Arcutis Biotherapeutics (ARQT), Nkarta (NKTX), Ocular Therapeutix (OCUL), Merus (MRUS), ImmunityBio (IBRX), PTC Therapeutics (PTCT), Agios Pharmaceuticals (AGIO), and Bausch Health Companies (BHC). These companies are all part of the "medical" sector. Phathom Pharmaceuticals vs. ORIC Pharmaceuticals Innoviva Arcutis Biotherapeutics Nkarta Ocular Therapeutix Merus ImmunityBio PTC Therapeutics Agios Pharmaceuticals Bausch Health Companies Phathom Pharmaceuticals (NASDAQ:PHAT) and ORIC Pharmaceuticals (NASDAQ:ORIC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, community ranking, risk and analyst recommendations. Does the MarketBeat Community believe in PHAT or ORIC? Phathom Pharmaceuticals received 24 more outperform votes than ORIC Pharmaceuticals when rated by MarketBeat users. However, 72.09% of users gave ORIC Pharmaceuticals an outperform vote while only 71.67% of users gave Phathom Pharmaceuticals an outperform vote. CompanyUnderperformOutperformPhathom PharmaceuticalsOutperform Votes8671.67% Underperform Votes3428.33% ORIC PharmaceuticalsOutperform Votes6272.09% Underperform Votes2427.91% Does the media favor PHAT or ORIC? In the previous week, ORIC Pharmaceuticals had 5 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 10 mentions for ORIC Pharmaceuticals and 5 mentions for Phathom Pharmaceuticals. Phathom Pharmaceuticals' average media sentiment score of 0.77 beat ORIC Pharmaceuticals' score of -0.11 indicating that Phathom Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phathom Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ORIC Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, PHAT or ORIC? Phathom Pharmaceuticals has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500. Comparatively, ORIC Pharmaceuticals has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500. Do insiders & institutionals have more ownership in PHAT or ORIC? 99.0% of Phathom Pharmaceuticals shares are held by institutional investors. Comparatively, 95.1% of ORIC Pharmaceuticals shares are held by institutional investors. 24.1% of Phathom Pharmaceuticals shares are held by insiders. Comparatively, 5.6% of ORIC Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Do analysts rate PHAT or ORIC? Phathom Pharmaceuticals presently has a consensus target price of $22.50, suggesting a potential upside of 156.26%. ORIC Pharmaceuticals has a consensus target price of $18.29, suggesting a potential upside of 115.13%. Given Phathom Pharmaceuticals' higher probable upside, equities research analysts plainly believe Phathom Pharmaceuticals is more favorable than ORIC Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Phathom Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75ORIC Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is PHAT or ORIC more profitable? ORIC Pharmaceuticals has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -1,292.14%. Phathom Pharmaceuticals' return on equity of 0.00% beat ORIC Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Phathom Pharmaceuticals-1,292.14% N/A -79.57% ORIC Pharmaceuticals N/A -42.47%-38.86% Which has higher earnings and valuation, PHAT or ORIC? ORIC Pharmaceuticals has lower revenue, but higher earnings than Phathom Pharmaceuticals. ORIC Pharmaceuticals is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPhathom Pharmaceuticals$680K882.91-$201.59M-$5.69-1.54ORIC PharmaceuticalsN/AN/A-$100.70M-$1.80-4.72 SummaryORIC Pharmaceuticals beats Phathom Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Ad Investors AlleyStrange: Why is Amazon suddenly yielding 39.70%?Something big is happening with Amazon stock… While most investors collect ZERO dividends from Amazon… A small group just discovered a "backdoor" way to collect yields up to 39.70%!Click here to see this breakthrough before everyone else → Get Phathom Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PHAT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHAT vs. The Competition Export to ExcelMetricPhathom PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$600.38M$6.39B$5.07B$8.66BDividend YieldN/A8.04%5.09%4.06%P/E Ratio-1.5410.88101.9417.40Price / Sales882.91245.131,197.2969.07Price / CashN/A53.4940.9636.36Price / Book-3.209.306.335.87Net Income-$201.59M$154.14M$119.64M$225.66M7 Day Performance-47.92%-9.47%-5.13%-1.34%1 Month Performance-45.94%-7.29%-2.72%1.15%1 Year Performance17.07%28.20%31.06%24.02% Phathom Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHATPhathom Pharmaceuticals2.8188 of 5 stars$8.78-3.4%$22.50+156.3%+19.8%$600.35M$680,000.00-1.54110ORICORIC Pharmaceuticals4.1718 of 5 stars$10.24-0.2%N/A+29.8%$722.35MN/A-5.8580Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageGap UpINVAInnoviva1.35 of 5 stars$20.13-0.2%N/A+38.5%$1.26B$352.75M29.17112News CoverageARQTArcutis Biotherapeutics2.0907 of 5 stars$10.80-0.2%N/A+374.9%$1.26B$138.71M-6.03150Positive NewsNKTXNkarta2.3504 of 5 stars$3.46+8.5%N/A+7.2%$244.14MN/A-1.84140OCULOcular Therapeutix4.0252 of 5 stars$10.81-2.6%N/A+340.4%$1.69B$58.44M-8.01267Analyst ForecastNews CoverageMRUSMerus1.88 of 5 stars$53.56-1.7%N/A+95.7%$3.67B$43.95M-13.5637Positive NewsIBRXImmunityBio0.7014 of 5 stars$5.24-5.9%N/A+9.8%$3.65B$1.31M-5.40590PTCTPTC Therapeutics2.7949 of 5 stars$45.99+3.9%N/A+96.2%$3.54B$937.82M-7.741,410News CoverageAGIOAgios Pharmaceuticals3.2983 of 5 stars$60.41+2.3%N/A+141.8%$3.45B$26.82M5.32390Short Interest ↑BHCBausch Health Companies2.7399 of 5 stars$9.36+0.2%N/A+29.3%$3.44B$9.47B-19.5020,270 Related Companies and Tools Related Companies ORIC Pharmaceuticals Alternatives Innoviva Alternatives Arcutis Biotherapeutics Alternatives Nkarta Alternatives Ocular Therapeutix Alternatives Merus Alternatives ImmunityBio Alternatives PTC Therapeutics Alternatives Agios Pharmaceuticals Alternatives Bausch Health Companies Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PHAT) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phathom Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Phathom Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
